MB, Levis & Associates’s VYNE Therapeutics VYNE Stock Holding History

MB, Levis & Associates’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$622	Hold	1,041	–	–	﹤0.01%	224
2025 Q4	$604	Hold	1,041	–	–	﹤0.01%	236
2025 Q3	$349	Hold	1,041	–	–	﹤0.01%	239
2025 Q2	$1.72K	Hold	1,041	–	–	﹤0.01%	246
2025 Q1	$1.65K	Hold	1,041	–	–	﹤0.01%	253
2024 Q4	$3.49K	Hold	1,041	–	–	﹤0.01%	234
2024 Q3	$1.96K	Hold	1,041	–	–	﹤0.01%	259
2024 Q2	$2.05K	Hold	1,041	–	–	﹤0.01%	257
2024 Q1	$3.2K	Hold	1,041	–	–	﹤0.01%	238
2023 Q4	$2.43K	Hold	1,041	–	–	﹤0.01%	243
2023 Q3	$4.21K	Hold	1,041	–	–	﹤0.01%	225
2023 Q2	$4.27K	Hold	1,041	–	–	﹤0.01%	223
2023 Q1	$3.21K	Sell	1,041 -1	-0.1%	-$4	﹤0.01%	236
2022 Q4	$2.81K	Buy	+1,042	New	+$4.17K	﹤0.01%	224

Other funds holding VYNE

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

T3 Companies New York $76.8M AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KCA

KVP Capital Advisors San Francisco, California $134M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MB, Levis & Associates's VYNE Position: Q1 2026 in Review

MB, Levis & Associates held its VYNE Therapeutics (VYNE) position steady in Q1 2026 at 1,041 shares worth $622. The position accounts for ﹤0.01% of the portfolio, ranked #224.

MB, Levis & Associates first reported a position in VYNE in Q4 2022 and has held it in 14 quarters since. The position peaked at $4.27K in Q2 2023. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

MB, Levis & Associates held 1,041 shares of VYNE Therapeutics worth $622 as of Q1 2026.
MB, Levis & Associates left its VYNE Therapeutics share count unchanged in Q1 2026.
VYNE Therapeutics made up ﹤0.01% of MB, Levis & Associates's portfolio in Q1 2026, its #224 holding.
MB, Levis & Associates first reported a position in VYNE Therapeutics in Q4 2022 and has held it in 14 quarters since.
MB, Levis & Associates's VYNE Therapeutics position peaked at $4.27K in Q2 2023.
45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on MB, Levis & Associates's 13F filing for Q1 2026, filed 8 Apr 2026.